Search research articles
Contact Us
Filters
Showing results (1-10 of 53) with videos related to
Page
of 6
Sort By:
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care
|
September 4, 2022
Cost-effectiveness of the MitraClip device in secondary mitral regurgitation: comment upon the article by Estler et al
Martin Connock, Xavier Armoiry
Heart (British Cardiac Society)
|
May 9, 2022
Correspondence on 'Cost-effectiveness of transcatheter edge-to-edge repair in secondary mitral regurgitation does need confirmation' by Cohen <i>et al</i>
Xavier Armoiry, Martin Connock
Pharmacoeconomics
|
July 21, 2011
Cautions regarding the fitting and interpretation of survival curves: examples from NICE single technology appraisals of drugs for cancer
Martin Connock, Chris Hyde, David Moore
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care
|
November 1, 2020
A comparison of published time invariant Markov models with Partitioned Survival models for cost effectiveness estimation; three case studies of treatments for glioblastoma multiforme
Martin Connock, Peter Auguste, Xavier Armoiry
International Journal of Technology Assessment in Health Care
|
April 25, 2019
How Do Pharmaceutical Companies Model Survival of Cancer Patients? A Review of NICE Single Technology Appraisals in 2017
Daniel Gallacher, Peter Auguste, Martin Connock
BMJ Open
|
December 11, 2024
Cost-effectiveness of percutaneous mitral repair for patients with severe secondary mitral regurgitation: an updated evaluation using a modelling approach based on COAPT final data after 5-year follow-up
Martin Connock, Peter Auguste, Jean-François Obadia, et al.
Plos One
|
November 9, 2020
Conflicting findings between the Mitra-Fr and the Coapt trials: Implications regarding the cost-effectiveness of percutaneous repair for heart failure patients with severe secondary mitral regurgitation
Xavier Armoiry, Jean-François Obadia, Peter Auguste, et al.
BJOG : an International Journal of Obstetrics and Gynaecology
|
October 18, 2005
Accuracy of ultrasound biometry in the prediction of macrosomia: a systematic quantitative review
Arri Coomarasamy, Martin Connock, Jim Thornton, et al.
Expert Opinion on Biological Therapy
|
May 22, 2020
Will the US$5 million onasemnogene abeparvosec treatment for spinal muscular atrophy represent 'value for money' for the NHS? A rapid inquiry into suggestions that it may be cost-effective
Martin Connock, Lazaros Andronis, Peter Auguste, et al.
Journal of Neuro-Oncology
|
May 26, 2019
Cost-effectiveness of tumor-treating fields added to maintenance temozolomide in patients with glioblastoma: an updated evaluation using a partitioned survival model
Martin Connock, Peter Auguste, Claude Dussart, et al.
Page
of 6
Search research articles
Search
Showing results (1-10 of 53) with videos related to
Sort By:
Page
of 6
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care
|
September 4, 2022
Cost-effectiveness of the MitraClip device in secondary mitral regurgitation: comment upon the article by Estler et al
Martin Connock, Xavier Armoiry
Heart (British Cardiac Society)
|
May 9, 2022
Correspondence on 'Cost-effectiveness of transcatheter edge-to-edge repair in secondary mitral regurgitation does need confirmation' by Cohen <i>et al</i>
Xavier Armoiry, Martin Connock
Pharmacoeconomics
|
July 21, 2011
Cautions regarding the fitting and interpretation of survival curves: examples from NICE single technology appraisals of drugs for cancer
Martin Connock, Chris Hyde, David Moore
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care
|
November 1, 2020
A comparison of published time invariant Markov models with Partitioned Survival models for cost effectiveness estimation; three case studies of treatments for glioblastoma multiforme
Martin Connock, Peter Auguste, Xavier Armoiry
International Journal of Technology Assessment in Health Care
|
April 25, 2019
How Do Pharmaceutical Companies Model Survival of Cancer Patients? A Review of NICE Single Technology Appraisals in 2017
Daniel Gallacher, Peter Auguste, Martin Connock
BMJ Open
|
December 11, 2024
Cost-effectiveness of percutaneous mitral repair for patients with severe secondary mitral regurgitation: an updated evaluation using a modelling approach based on COAPT final data after 5-year follow-up
Martin Connock, Peter Auguste, Jean-François Obadia, et al.
Plos One
|
November 9, 2020
Conflicting findings between the Mitra-Fr and the Coapt trials: Implications regarding the cost-effectiveness of percutaneous repair for heart failure patients with severe secondary mitral regurgitation
Xavier Armoiry, Jean-François Obadia, Peter Auguste, et al.
BJOG : an International Journal of Obstetrics and Gynaecology
|
October 18, 2005
Accuracy of ultrasound biometry in the prediction of macrosomia: a systematic quantitative review
Arri Coomarasamy, Martin Connock, Jim Thornton, et al.
Expert Opinion on Biological Therapy
|
May 22, 2020
Will the US$5 million onasemnogene abeparvosec treatment for spinal muscular atrophy represent 'value for money' for the NHS? A rapid inquiry into suggestions that it may be cost-effective
Martin Connock, Lazaros Andronis, Peter Auguste, et al.
Journal of Neuro-Oncology
|
May 26, 2019
Cost-effectiveness of tumor-treating fields added to maintenance temozolomide in patients with glioblastoma: an updated evaluation using a partitioned survival model
Martin Connock, Peter Auguste, Claude Dussart, et al.
Page
of 6